Oppenheimer Downgrades Sarepta Therapeutics (SRPT) to Perform, seeks "greater clarity on FDA feedback, timelines for potential full approval, full safety dataset"
Tweet Send to a Friend
(Updated - October 31, 2023 6:54 AM EDT)
Oppenheimer analyst Hartaj Singh downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Hartaj Singh downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
